Abbott Laboratories (ABT)

$117.76

+0.5

(+0.43%)▲

Market is closed - opens 8 PM, 25 Nov 2024
star icon

Abbott Laboratories is a global healthcare company that specializes in the discovery, development, and manufacturing of innovative medical devices and diagnostics.

Performance

  • $116.47
    $117.95
    $117.76
    downward going graph

    1.1%

    Downside

    Day's Volatility :1.25%

    Upside

    0.16%

    downward going graph
  • $99.71
    $121.64
    $117.76
    downward going graph

    15.33%

    Downside

    52 Weeks Volatility :18.03%

    Upside

    3.19%

    downward going graph

Returns

PeriodAbbott LaboratoriesSector (Health Care)S&P500
3 Months
4.5%
-7.3%
5.9%
6 Months
12.98%
-0.5%
13.3%
1 Year
14.47%
10.5%
31.0%
3 Years
-5.4%
8.8%
27.3%

Highlights

Market Capitalization
203.4B
Book Value
$22.94
Dividend Share
2.2
Dividend Yield
1.9%
Earnings Per Share (EPS)
3.29
PE Ratio
35.64
PEG Ratio
2.25
Wall Street Target Price
129.871
Profit Margin
13.99%
Operating Margin TTM
18.75%
Return On Assets TTM
6.49%
Return On Equity TTM
14.84%
Revenue TTM
41.2B
Revenue Per Share TTM
23.68
Quarterly Revenue Growth YOY
4.9%
Gross Profit TTM
24.6B
EBITDA
10.8B
Diluted Eps TTM
3.29
Quarterly Earnings Growth YOY
0.15
EPS Estimate Current Year
4.68
EPS Estimate Next Year
5.16
EPS Estimate Current Quarter
1.2
EPS Estimate Next Quarter
1.34

Analyst Recommendation

Buy
    75%Buy
    24%Hold
    0
    0%Sell
Based on 29 Wall street analysts offering stock ratings for Abbott Laboratories(by analysts ranked 0 to 5 stars)
Based on 29 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
22
22
21
Hold
7
7
7
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 10.28%

Current $117.76
Target $129.87

Company Financials

FY18Y/Y Change
Revenue
30.6B
↑ 11.64%
Net Income
2.4B
↑ 396.44%
Net Profit Margin
7.74%
↑ 6.0%
FY19Y/Y Change
Revenue
31.9B
↑ 4.34%
Net Income
3.7B
↑ 55.7%
Net Profit Margin
11.56%
↑ 3.82%
FY20Y/Y Change
Revenue
34.6B
↑ 8.48%
Net Income
4.5B
↑ 21.91%
Net Profit Margin
12.99%
↑ 1.43%
FY21Y/Y Change
Revenue
43.1B
↑ 24.47%
Net Income
7.1B
↑ 57.31%
Net Profit Margin
16.42%
↑ 3.43%
FY22Y/Y Change
Revenue
43.7B
↑ 1.34%
Net Income
6.9B
↓ 1.95%
Net Profit Margin
15.88%
↓ 0.54%
FY23Y/Y Change
Revenue
40.1B
↓ 8.12%
Net Income
5.7B
↓ 17.45%
Net Profit Margin
14.27%
↓ 1.61%
Q2 FY23Q/Q Change
Revenue
10.0B
↑ 2.37%
Net Income
1.4B
↑ 4.32%
Net Profit Margin
13.78%
↑ 0.26%
Q3 FY23Q/Q Change
Revenue
10.1B
↑ 1.65%
Net Income
1.4B
↑ 4.44%
Net Profit Margin
14.16%
↑ 0.38%
Q4 FY23Q/Q Change
Revenue
10.2B
↑ 0.97%
Net Income
1.6B
↑ 11.0%
Net Profit Margin
15.56%
↑ 1.4%
Q1 FY24Q/Q Change
Revenue
10.0B
↓ 2.7%
Net Income
1.2B
↓ 23.15%
Net Profit Margin
12.29%
↓ 3.27%
Q2 FY24Q/Q Change
Revenue
10.4B
↑ 4.14%
Net Income
1.3B
↑ 6.29%
Net Profit Margin
12.55%
↑ 0.26%
Q3 FY24Q/Q Change
Revenue
10.6B
↑ 2.49%
Net Income
1.6B
↑ 26.42%
Net Profit Margin
15.48%
↑ 2.93%
FY18Y/Y Change
Total Assets
67.2B
↓ 11.9%
Total Liabilities
36.5B
↓ 19.27%
FY19Y/Y Change
Total Assets
67.9B
↑ 1.06%
Total Liabilities
36.6B
↑ 0.37%
FY20Y/Y Change
Total Assets
72.5B
↑ 6.87%
Total Liabilities
39.5B
↑ 8.09%
FY21Y/Y Change
Total Assets
75.2B
↑ 3.65%
Total Liabilities
39.2B
↓ 0.94%
FY22Y/Y Change
Total Assets
74.4B
↓ 1.01%
Total Liabilities
37.5B
↓ 4.18%
FY23Y/Y Change
Total Assets
73.2B
↓ 1.64%
Total Liabilities
34.4B
↓ 8.38%
Q2 FY23Q/Q Change
Total Assets
73.4B
↓ 0.6%
Total Liabilities
36.0B
↓ 1.67%
Q3 FY23Q/Q Change
Total Assets
72.1B
↓ 1.72%
Total Liabilities
34.4B
↓ 4.32%
Q4 FY23Q/Q Change
Total Assets
73.2B
↑ 1.56%
Total Liabilities
34.4B
↓ 0.03%
Q1 FY24Q/Q Change
Total Assets
72.5B
↓ 1.02%
Total Liabilities
33.4B
↓ 2.8%
Q2 FY24Q/Q Change
Total Assets
73.0B
↑ 0.76%
Total Liabilities
33.5B
↑ 0.1%
Q3 FY24Q/Q Change
Total Assets
74.4B
↑ 1.83%
Total Liabilities
34.3B
↑ 2.6%
FY18Y/Y Change
Operating Cash Flow
6.3B
↑ 13.11%
Investing Cash Flow
-1.4B
↓ 85.9%
Financing Cash Flow
-10.4B
↑ 96.76%
FY19Y/Y Change
Operating Cash Flow
6.1B
↓ 2.6%
Investing Cash Flow
-1.8B
↑ 33.85%
Financing Cash Flow
-4.3B
↓ 58.72%
FY20Y/Y Change
Operating Cash Flow
7.9B
↑ 28.76%
Investing Cash Flow
-2.2B
↑ 22.04%
Financing Cash Flow
-2.8B
↓ 35.21%
FY21Y/Y Change
Operating Cash Flow
10.5B
↑ 33.31%
Investing Cash Flow
-2.0B
↓ 9.35%
Financing Cash Flow
-5.5B
↑ 97.7%
FY22Y/Y Change
Operating Cash Flow
9.6B
↓ 9.04%
Investing Cash Flow
-1.7B
↓ 13.35%
Financing Cash Flow
-7.6B
↑ 38.99%
Q2 FY23Q/Q Change
Operating Cash Flow
1.2B
↑ 5.25%
Investing Cash Flow
-1.2B
↑ 162.55%
Financing Cash Flow
-1.3B
↓ 8.58%
Q3 FY23Q/Q Change
Operating Cash Flow
1.9B
↑ 56.03%
Investing Cash Flow
-634.0M
↓ 47.73%
Financing Cash Flow
-2.3B
↑ 81.54%

Technicals Summary

Sell

Neutral

Buy

Abbott Laboratories is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Abbott Laboratories
Abbott Laboratories
0.64%
12.98%
14.47%
-5.4%
39.38%
Johnson & Johnson
Johnson & Johnson
-6.45%
3.65%
1.75%
-3.44%
13.11%
Pfizer Inc.
Pfizer Inc.
-11.12%
-10.6%
-15.9%
-49.78%
-33.69%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Abbott Laboratories
Abbott Laboratories
35.64
35.64
2.25
4.68
0.15
0.06
0.02
22.94
Johnson & Johnson
Johnson & Johnson
25.45
25.45
0.92
9.96
0.21
0.08
0.03
29.14
Pfizer Inc.
Pfizer Inc.
33.51
33.51
0.18
2.93
0.05
0.03
0.07
16.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Abbott Laboratories
Abbott Laboratories
Buy
$203.4B
39.38%
35.64
13.99%
Johnson & Johnson
Johnson & Johnson
Buy
$370.8B
13.11%
25.45
16.74%
Pfizer Inc.
Pfizer Inc.
Hold
$142.4B
-33.69%
33.51
7.16%

Insights on Abbott Laboratories

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 9.96B → 10.63B (in $), with an average increase of 3.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 1.22B → 1.64B (in $), with an average increase of 13.4% per quarter

  • Vs JNJ

    In the last 3 years, Abbott Laboratories has experienced a drawdown of -5.4%, however Johnson & Johnson resisted the overall trend and outperformed by 2.0%

Institutional Holdings

  • Vanguard Group Inc

    9.68%

  • BlackRock Inc

    7.56%

  • State Street Corp

    4.29%

  • Morgan Stanley - Brokerage Accounts

    4.11%

  • Capital Research & Mgmt Co - Division 3

    3.79%

  • Capital Research Global Investors

    3.07%

Corporate Announcements

  • Abbott Laboratories Dividends March,2024

    In the quarter ending March,2024. Abbott Laboratories has declared dividend of $0.55

    Read More

Company Information

Abbott Laboratories, headquartered in Chicago, Illinois, was founded in 1888 by a physician named Dr Wallace Calvin. His purpose was to improve people's well-being and help them reach their full potential at different stages of their lives. Founded as a drug formulation company, today, Abbott Laboratories is a worldwide leader in healthcare, medical devices, nutritional products, and pharmaceutical drugs. Even though it reached the shores of India a century ago, it is still regarded as one of the largest healthcare product companies. With a focus on cardiovascular, diagnostic, diabetes, and neuromodulation products, some of its popular brands include Pedialyte, Glucerna, Similac, Ensure, and iStat. Abbott opened its first international office in London in 1907, and currently operates in over 160 countries. Its growth is also a result of strategic acquisitions. Abbott’s recent acquisitions include Kalo Pharma International in 2014, which doubled its brand generic drug portfolio. It acquired Tendyne in 2015 and along with it the company’s minimally invasive mitral valve replacement therapies. Another gem in the crown is the acquisition of Alere in 2016, which gave Abbott access to the largest mail-order diabetic supplier, Arriva Medical. Along with strategic acquisitions, the company is dedicated to gaining a strong competitive advantage. With the onset of COVID-19, the company has developed various antibody tests that have been granted emergency-use authorization. According to Forbes, Abbott Laboratories' fast and low-cost testing methods have expedited the detection of COVID-19 virus. For its 2030 sustainability plan, the company is gearing up to introduce revolutionary products such as BinaxNOW, a COVID-19 test, and FreeStyle Libre, an innovative glucose monitoring device. Abbott’s future plans are centred around providing cutting-edge technologies at affordable prices to even the most vulnerable sections of society. Currently Abbott Laboratories has a market cap of $196.19 Billion. It has a P.E ratio of 35.31. The shares of Abbott Laboratories are trading at $117.76. .

Organization
Abbott Laboratories
Employees
114000
CEO
Mr. Robert B. Ford
Industry
Health Technology

FAQs